tbuckley/cabot-search huggingface dataset:
Abstract 4774: Epimorphin inhibits mammary epithelial cell apoptosis through induction of IKBKE
Authors: Davitte Khauv, Magdalena Cichon, Derek Radisky
Journal: Cancer Research (2011)

Abstract Epimorphin is a stromally produced factor that plays a role in normal mammary branching morphogenesis, but deregulated expression of epimorphin can have oncogenic consequences, although the oncogenic processes activated by epimorphin have not been elucidated. We had previously found that treatment of cultured mammary epithelial cells with epimorphin blocked activation of cell death pathways by a variety of apoptotic stimuli. These results implicated a potential role for epimorphin for inhibition of cellular apoptosis, a critical stage of tumor development. To identify potential mediators by which epimorphin could be affecting cell death pathways, we used a transcriptional profiling approach comparing mammary epithelial cells treated with epimorphin versus untreated cells. We found that epimorphin treatment led to significantly increased expression of IKBKE, which inhibits apoptosis through activation of NF-kappaB and which has recently been characterized as a key breast cancer oncogene. We found that epimorphin specifically blocks induction of apoptosis and activation of caspase-3 in cells treated with tumor necrosis factor-alpha, and that this activity was linked to epimorphin-mediated activation of IKBKE. We also found that knockdown of IKBKE blocked epimorphin-mediated induction of branching morphogenesis, implicating activation of IKBKE by epimorphin as a critical function for its normal morphogenic activities as well. These studies provide insight into an additional and unexpected linkage between mammary gland developmental processes and breast cancer progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4774. doi:10.1158/1538-7445.AM2011-4774
Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis
Authors: Pau Sort, Miquel Navasa, Vicente Arroyo, Xavier Aldeguer, Ramon Planas, Luis Ruiz-del-Arbol, Lluis Castells, Victor Vargas, Germán Soriano, Mónica Guevara, Pere Ginès, Joan Rodés
Journal: New England Journal of Medicine (1999)

In patients with cirrhosis and spontaneous bacterial peritonitis, renal function frequently becomes impaired. This impairment is probably related to a reduction in effective arterial blood volume and is associated with a high mortality rate. We conducted a study to determine whether plasma volume expansion with intravenous albumin prevents renal impairment and reduces mortality in these patients.
Fallback Cuts or Super-Committee Concoction — Choosing Health Care's Policy Poison
Authors: Christopher C. Jennings
Journal: New England Journal of Medicine (2011)

When the compromise on extending the debt limit was struck and enacted into Public Law 112-25 in early August, both President Barack Obama and the Republican congressional leadership stated that the law's painful fallback budget cuts would probably not be triggered. They asserted that their very existence would motivate lawmakers (through the newly established congressional joint committee, better known as the super committee) to compromise on a thoughtful, policy-oriented deficit- and debt-reducing alternative to meet the law's required second round of cuts. The theory was that the $1.2 trillion in automatic cuts to popular programs such as the military and . . .
Abstract P4-02-06: Molecular imaging with trastuzumab and pertuzumab of HER2-positive breast cancer in mice: a step towards personalized medicine
Authors: B Collin, A Oudot, J-M Vrigneaud, M Moreau, O Raguin, O Duchamp, X Tizon, F Denat, N Varoqueaux, F Brunotte, P Fumoleau
Journal: Cancer Research (2012)

Abstract Introduction: The accurate and reliable assessment of HER2 status is an essential step in the diagnostic workup and selection of targeted treatment strategy in breast cancer patients. However, current ex vivo methods do not evaluate HER2 status possible discordance between primary tumor and distant metastases, nor immediate response to therapeutic intervention. Non-invasive imaging of HER2 expression could be a relevant alternative with additional benefits such as a better selection of patients for HER2-targeted therapies and the possible optimization of treatment strategies. Recent clinical trials suggest a better efficacy of trastuzumab/pertuzumab doublet but a lower activity of pertuzumab monotherapy over trastuzumab alone. Aim: The aim of our study was therefore to evaluate preclinically the use of radiolabeled DOTAGA (2, 2′, 2″-(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid) conjugated trastuzumab and pertuzumab for SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) HER2 imaging purposes. Methods: Trastuzumab and pertuzumab were conjugated to a new bifunctional chelating agent: DOTAGA anhydride (DOTA analog) and subsequently radiolabeled with the gamma-emitter Indium 111. The functionality of [111In]-DOTAGA-antibodies analogs was evaluated by in vitro saturation assays using HER2-overexpressing human breast cancer cell line (HCC1954). In vivo biodistribution was studied by SPECT/CT imaging at 24h, 48h and 72h after intravenous injection of [111In]-DOTAGA-antibodies in subcutaneous BT474 tumor-bearing rodents. Results: [111In]-DOTAGA-trastuzumab and [111In]-DOTAGA-pertuzumab showed respectively 2.6 and 2.7 DOTAGA/antibody. Both [111In]-DOTAGA-trastuzumab and [111In]-DOTAGA-pertuzumab achieved a radiochemical purity &amp;gt; 95%. Biological activity of [111In]-DOTAGA-trastuzumab and [111In]-DOTAGA-pertuzumab was maintained: the affinity determined on HER2 expressing HCC1954 cell lines, was 5.5 and 5.6 nM. SPECT/CT imaging experiments in tumor-bearing rodents and gamma-counting of organs both showed that at 72h post-injection, more than 60 % of the activity was localized in the tumor (66.9±0.9 %ID/g for [111In]-DOTAGA-trastuzumab and 63.8±6.3 %ID/g for [111In]-DOTAGA-pertuzumab) and that an excess of non-radiolabeled corresponding antibody significantly shifted down tumor-targeting (to 17.6±2.4 %ID/g for [111In]-DOTAGA-trastuzumab and 8.7±0.8 %ID/g for [111In]-DOTAGA-pertuzumab. Conclusions: Our results demonstrate a similar HER2 binding of trastuzumab and pertuzumab. Both radiolabeled [111In]-DOTAGA-trastuzumab and [111In]-DOTAGA-pertuzumab should be considered and might be promising tools for molecular imaging diagnosis of HER2 overexpression in breast cancer. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-02-06.
ZILVER PTX DRUG-COATED PERIPHERAL ARTERY STENT USE IN A U.S. MULTICENTER REGISTRY
Authors: Karan Sarode, Atif Mohammad, Osvaldo Gigliotti, Michael Luna, Tayo Addo, Mirza Baig, Shirling Tsai, Nicolas Shammas, Anand Prasad, Mazen Abu-Fadel, Andrew Klein, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2015)
Nocturnal Animals Help Shed Light on Human Melanoma
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Nocturnal Animals Help Shed Light on Human Melanoma Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 21, 1 November 1995, Pages 1584–1585, https://doi.org/10.1093/jnci/87.21.1584 Published: 01 November 1995
The efficiency of endoscopic ultrasound in pretherapeutic assessment of the depth of invasion in early gastric cancer
Authors: EY Kim, JY Cho, JK Jeong, J Han, JH Choi, JT Jung, JG Kwon, CH Lee, HG Kim, CH Cho, KH Park
Journal: Endoscopy (2006)

Aim: Increased applications of endoscopic mucosal resection (EMR) and laparoscopic surgery accentuate the importance of accurate evaluation of the depth of invasion in the treatment of early gastric cancer (EGC). We evaluated the efficiency of endoscopic ultrasonography (EUS) in the staging of EGC. Methods: The accuracy of EUS in pretherapeutic evaluation of EGC was analyzed retrospectively. Pathologically proven 53 gastric cancers with suspicion of early stage by endoscopy and CT were evaluated with EUS followed by surgical (37 cases) or endoscopic resections (16 cases). The results of EUS staging were compared to the postresection histological staging. Results: The overall accuracy of EUS in differentiation between mucosal (m) and submucosal (sm) cancer was 62.3%. The depth of m and sm cancers was correctly assessed by EUS as 58% and 70%, respectively. The rate of overstaging was 32.1%(17/53) while that of understaging was only 5.7%(3/53). One case of EMR needed further treatment. Statistical analysis was carried out to verify the factors that affect the accuracy of EUS. The included variables were size, groß type, site, differentiation, associated intestinal metaplasia, and Ming & Lauren classification of tumor. Differentiation of tumor showed statistical significance (p<0.03) on diagnostic accuracy of EUS. Well differentiated adenocarcinoma had the tendency of accurate EUS staging. Conclusions: Endoscopic mucosal resection is a good modality for the treatment of EGC. However, when the patients are not accurately selected, EMR should be followed by additional second stage surgical treatment. Although the accuracy of EUS in differentiation of m and sm gastric cancer was relatively lower in this study, higher accuracy in well differentiated adenocarcinoma and the overstaging tendency have positive aspect of reducing the necessity of second stage operation.
P55 TB risk after new immigrant GP registration: a retrospective cohort analysis
Authors: R. K. Panchal, P. Haldar, G. Woltmann
Journal: Thorax (2011)

<h3>Introduction</h3> Although 80% of all TB cases in the UK occur in foreign born persons, TB risk in the immigrant population is largely unknown due to uncertain estimates of migration. The evaluation of screening models to prevent immigrant TB depends on informed estimations of this risk. <h3>Objective</h3> To evaluate TB risk in a cohort of immigrants with new immigrant GP registration status (Flag-4) in Leicestershire; and to estimate efficacy of a screening model that uses Flag-4 registration and testing with interferon gamma release assays (IGRAs) for identifying latent infection with <i>M tuberculosis</i> (LTBI). <h3>Methods</h3> All Flag-4 registered immigrants between January 2000 and December 2010 were included and collated with TB notification data for the same period. TB cases arising in registered immigrants were included for estimation of case rate using Kaplan–Meier curves. Cumulative TB rates were expressed as time after UK entry and time after GP registration and compared between immigrant subgroups stratified by WHO incidence in country of origin (150–499/100 000 or 500+/100 000) and age group at time of registration (&lt;16, 16–35 or =36 years). The number needed to screen was calculated using an overall prevalence estimate of 25% IGRA positivity, with all cases occurring in this subgroup. <h3>Results</h3> 564 cases were recorded in 34 764 immigrants. The median (IQR) observation was 2198 (982–3329) days after UK entry and 956 (358–1888) days after GP registration. There was no difference in risk with time after UK entry or GP registration and the TB rate rose linearly over 10 years. In our cohort, the 5-year cumulative TB rate was significantly higher for immigrants from regions with incidence of 150–499 than those from 500+. The TB rate was also significantly higher in adults than children, and highest in adults aged 16–35 years (Abstract P55 table 1). For this age band, the estimated number needed to screen (95% CI) with IGRAs to identify one immigrant developing TB in 5 years was 78.8 (73.2–85.2) persons. <h3>Conclusions</h3> A new immigrant screening model using the Flag 4 GP registry and IGRA testing may be effective for identifying at-risk immigrants.
INFLAMMATORY ACTIVITY OF PERICORONARY ADIPOSE TISSUE IN PATIENTS WITH NSTE-ACS AND INSULIN RESISTANCE
Authors: Tomasz Mazurek, Malgorzata Kobylecka, Janusz Kochman, Krzysztof Filipiak, Leszek Krolicki, Grzegorz Opolski
Journal: Journal of the American College of Cardiology (2015)
Ultrasonic vs. hand instrumentation in periodontal therapy: clinical outcomes
Authors: Ranjitha Krishna, Jamie A. De Stefano
Journal: Periodontology 2000 (2016)

Abstract Periodontal disease is the most common oral disease in adults. Traditional nonsurgical periodontal therapy involves subgingival removal of hard and soft deposits on the root surface, along with maintenance of good oral hygiene. Nonsurgical periodontal therapy can either be definitive or part of the initial phase before surgical therapy. Mechanical therapy, either with hand or ultrasonic instrumentation, is the keystone of nonsurgical periodontal therapy. This requires considerable amounts of time and a high level of operator skill. The use of appropriate instruments greatly increases clinical efficiency. This article discusses the use of ultrasonic and hand instrumentation, along with recent advances, and the benefits of adjunctive therapy during nonsurgical periodontal therapy.
Pseudomelanosis ilei associated with ingestion of oral iron therapy
Authors: R. Kibria, S. Ali, S. Akram
Journal: Endoscopy (2010)

A 63-year-old man was seen in consultation for iron deficiency anemia without overt bleeding. Other problems included depression, hypertension, and aortic valve insufficiency. Medications included escitalopram oxalate, metoprolol, and furosemide. Upper endoscopy with small-bowel biopsies was normal. Colonoscopy revealed a 1.5-cm sessile polyp in the descending colon, which was removed with hot snare polypectomy. Examination of the terminal ileum was unremarkable. Histopathology revealed villous adenoma with low grade dysplasia. The patient began therapy with ferrous sulfate for his iron deficiency. His anemia resolved and his iron counts returned to normal.
AB0469 Fibrinolytic parameters abnormalities in tunisian patients with behçet’s disease. correlations with clinical presentation, activity, and severity of the disease.
Authors: M. Smiti Khanfir, N. Belfeki, H. Baccouche, A. Hamzaoui, T. Ben Salem, S. Mahjoub, I. Ben Ghorbel, M. Lamloum, N. Ben Romdhane, M. H. Houman
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The pathogenesis of Behçet’s disease (BD) remains unsolved. Endothelial damage and/or defects in coagulation or fibrinolysis are thought to take a part. <h3>Objectives</h3> Our aim was to determine d-dimers levels, tissue type plasminogen activator (t-PA), and plasminogen activator inhibitor 1 (PAI-1) in Tunisian patients with BD and to compare them with matched healthy controls. We also investigated the relation of these findings to patients’ clinical features, activity and severity. <h3>Methods</h3> The patient group included 57 BD (International Study Group criteria). According to the Yosipovitch severity scale, patients were divided into three subgroups: mild, moderate and severe disease. The activity index has been elaborated according to the Yazici scale. We excluded all patients with other physiological and pathological situations that may increase d-dimer. The control group consisted of Tunisian healthy individuals matched for age and sex. Levels of d-dimers were determined by a quantitative assay test and Plasma concentrations of t-PA and PAI-1 were determined by enzyme linked immunoabsorbent assay (ELISA). <h3>Results</h3> We included 57 BD patients (sex ratio M/F: 42/15, mean age: 40 years). One patient was excluded from statistical analysis due to a high rate of d-dimers (10µg/ml). The frequency of positive d-dimer was significantly higher in BD ptients than in healthy controls (17 (30%) vs 8 (13.8%) p=0.03). Table 1 summarizes the variation of d-dimer’s positivity according to demographic characteristics, clinical features, activity scale, and severity in BD patients. Financial limitations allowed us to realize t-Pa determination only in 42 patients and 44 healthy controls. The average rate of t-PA patients (4.85 ± 7.36 ng / ml) was lower than that of controls (5.62 ± 8.49 ng/ml). No significant correlation was found between the average t-PA, clinical manifestations and disease activity. The comparison of the frequencies of the different clinical manifestations depending on the average of PAI-1 showed a significantly lower level during ocular involvement (p=0.03). Average rates of PAI-1 were elevated in active forms of the disease. <h3>Conclusions</h3> The scarcity of publications on fibrinolytic abnormalities in BD does not help us to an easy interpretation of these results and their implication in the pathogenesis of the disease as a causative agent or a consequence, even if this seems to be most likely. <h3>Disclosure of Interest</h3> None Declared
Cancer Workup after Unprovoked Clot — Less Is More
Authors: Alok A. Khorana
Journal: New England Journal of Medicine (2015)

Consider this not unfamiliar scenario: a 56-year-old educator presents with sudden onset of swelling and pain in the right thigh. She has no coexisting conditions except for well-controlled hypertension and has no family history of thrombophilia. She is admitted to the hospital after compression ultrasonography reveals the presence of a femoral-vein thrombosis. There are no provoking factors such as recent surgery or hospitalization. The phrase “possible cancer” is brought up on rounds, despite the patient’s recent normal results on colonoscopy and mammography. The patient is anxious about undiagnosed cancer and asks whether extensive imaging to rule out cancer is needed. . . .
Accuracy of MRI in selecting patients for breast conserving therapy after neoadjuvant chemotherapy.
Authors: ME Straver, CE Loo, MT Vrancken-Peeters, EJ Rutgers, K Gilhuijs
Journal: Cancer Research (2009)

Abstract Abstract #4006 Introduction: Accurate assessment of the extent of residual breast cancer is crucial for the surgical planning after neoadjuvant chemotherapy (NAC). Compared to conventional imaging, MRI shows superior ability to monitor tumor response. Nonetheless, controversy exists about the precision of MRI to visualize disease extent after NAC. The aim of this study was to determine which variables influence the accuracy of MRI.&amp;#x2028; Methods: Retrospective analysis of 130 patients treated with NAC. Contrast-enhanced MRI studies were performed on a 1.5-T scanner with a dedicated breast coil before, during and after NAC. The outcome parameters were the accuracy of the estimation of tumor size on final MRI and the accuracy in predicting the ability to perform breast conserving therapy (BCT). Tumor size on the final MRI was therefore compared to residual tumor size on pathology. Discrepancy &amp;lt;10 mm between MRI and pathology was defined as correct prediction. Patients with a tumor size &amp;lt;30 mm on MRI were considered indicative for BCT. The MRI indication for BCT was compared with the surgical treatment feasible based on size on pathology.&amp;#x2028; Results: In 61/130 patients (47%) the difference between size on MRI and size on pathology was &amp;gt;10 mm. In 50% (n=32) this discrepancy between pathology and MRI would lead to different surgical treatment. Based on the MRI indication for BCT, 19 patients would have unjustly undergone BCT (disease extent at MRI &amp;lt;30 mm and disease extent at pathology &amp;gt;30 mm). In 13 patients MRI alone would have led to mastectomy (extent &amp;gt;30 mm) while the actual extent at pathology was &amp;lt;30 mm. Thus, MRI accurately indicated selection of surgical treatment in 98 patients (75%). Inaccurate indication (25%) was caused by underestimation as well as overestimation of disease extent. Variables significantly influencing the accuracy of MRI were type of lesion on baseline MRI, pattern of tumor decline, histological and molecular subtype.&amp;#x2028; &amp;#x2028; Conclusions: The results show the strengths and limitations in monitoring tumor response with MRI. For preoperative assessment the final MRI should be evaluated with the knowledge of the baseline MRI and the molecular and histological subtype. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4006.
P3-01-09: Oncogenic Activation of HSF1 Enables the Malignant Progression of Breast Carcinoma.
Authors: ML Mendillo, S Santagata, M Koeva, E Fraenkel, TA Ince, L Whitesell, S Lindquist
Journal: Cancer Research (2011)

Abstract HSF1 is best known for its role as the master transcriptional regulator of the evolutionarily conserved heat-shock response. In mice, Hsf1 knock-outs dramatically reduce susceptibility to malignant transformation and tumor formation, and markedly increased survival in cancers driven by both oncogenic and tumor suppressor mutations. Likewise, RNAi-mediated knockdown markedly reduces the growth and survival of human cell lines established from cancers driven by a diversity of genetic lesions. The transcriptional network that HSF1 coordinates during heat-shock is known, but is unknown in malignancy. We compare HSF1 function in isogenic breast cancer cells of high and low malignant potential. HSF1 orchestrates a far-reaching transcriptional program that is dependent on transformation and the degree of malignancy. The oncogenic HSF1 program differs markedly from the classical heat-shock response. It is enriched for genes involved in a myriad of cellular processes known to be important in malignancy, including transcription, translation, glucose metabolism and cellular adhesion. It includes only a particular subset of heat-shock protein genes, and many of these are regulated in a manner that differs from their regulation by heat-shock. We also find that HSF1 is overexpressed and activated in a large subset of all conventionally defined classes of breast cancer. Moreover, tumors with high expression of the oncogenic HSF1 transcriptional network are strongly associated with poor outcome as monitored by metastasis and death. Our findings suggest that the oncogenic HSF1 activation program is rooted in fundamental aspects of tumor biology and will prove a powerful new tool in the clinical management of patients with breast cancer and, likely, other malignancies as well. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-01-09.